Navigation Links
AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
Date:9/5/2007

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Sept. 5 /PRNewswire-FirstCall/ - AKELA Pharma Inc., (TSX: AKL), a drug development company focused on developing therapies for the inhalation, pain and CNS markets, today announced positive results from the double-blind extension part of its Fentanyl TAIFUN(R) Phase IIb trial. The results demonstrated statistically significant differences compared to placebo in the measured primary and secondary efficacy variables resulting in faster and superior pain relief. Fentanyl TAIFUN(R) is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform.

A total of 50 patients were randomized and started the extension part of the study. In the Intent-To-Treat (ITT) population, the median time to significant pain relief in the Fentanyl TAIFUN(R) group as measured by a decrease of at least 2 points on the numerical pain scale (NPS) was 5.2 minutes, which was statistically significantly faster when compared to placebo (P=0.007). The mean difference in sum of pain intensity difference (SPID) was also statistically significantly in favor of Fentanyl TAIFUN(R) for the whole 60 min pain episode (P=0.050). This was already seen in numerical pain scale scores up to 15 minutes (P=0.008) when compared to placebo.

"We are extremely satisfied to have demonstrated beyond doubt the faster and superior pain relief provided by Fentanyl TAIFUN(R) to patients. The additional knowledge and data accumulated during this clinical trial, as well as the positive feed-back by the authorities during the recent End-of-Phase II meetings makes us confident when preparing our Phase III study protocols." said Dr. Halvor Jaeger, Chief Executive Officer of Akela Pharma Inc.

Phase IIb for Fentanyl TAIFUN(R) was a multi-center, multinational clinical trial in cancer patients with severe persistent pain on maintenance opioid therapy. The first part of the trial was a single arm, open-label dose titration to evaluate the effective individual dose for significant pain relief with Fentanyl TAIFUN(R) in the treatment of breakthrough cancer pain. The second part included responders from the open-label part randomized to receive the titrated doses or placebo.

Chronic pain associated with advanced cancer is commonly treated with strong opioid analgesics, such as fentanyl. Breakthrough pain episodes are sudden and intense flares of pain that "break through" a long-acting continuous treatment, such as a transdermal patch or a slow release tablet. Breakthrough pain episodes are common in cancer patients, often occurring several times a day.

Conference call information:

Akela will host a conference call at 11:00 am, on Wednesday September 5, 2007. Interested parties may also access the conference call by webcast at http://www.akelapharma.com.

The telephone number to access the conference call is 1-800-731-5319. A replay of the call will be available until Wednesday September 12, 2007. The telephone numbers to access the replay are 416-640-1917 and 1-877-289-8525 with code number 21245927#.

About Akela Pharma Inc.

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation, pain and CNS markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 82.3 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of AKELA Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE AKELA PHARMA INC.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. India to benefit from pharma companies move
2. South Africa Wins landmark case against pharmaceutical giants
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
5. Pharma cos must forge Strategic alliances
6. Setting up a new pharmaceutical industry in India
7. Medicis Pharmaceutical company enters pediatric market
8. Supply of Radiopharmaceuticals Hampered by Attacks
9. Pharma majors gear to supply anti-anthrax drug
10. Pharmacies in for a dose of bitter medicine
11. Andhra Pradesh to set up Pharma City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology: